Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus |
Domain |
PF00307 Calponin homology (CH) domain PF01494 FAD binding domain PF00412 LIM domain |
Function |
Nuclear monooxygenase that promotes depolymerization of F-actin by mediating oxidation of specific methionine residues on actin to form methionine-sulfoxide, resulting in actin filament disassembly and preventing repolymerization. In the absence of actin, it also functions as a NADPH oxidase producing H(2)O(2) (By similarity). Acts as a key regulator of the SRF signaling pathway elicited by nerve growth factor and serum: mediates oxidation and subsequent depolymerization of nuclear actin, leading to increase MKL1/MRTF-A presence in the nucleus and promote SRF:MKL1/MRTF-A-dependent gene transcription. Does not activate SRF:MKL1/MRTF-A through RhoA. |
Biological Process |
GO:0001947 heart looping GO:0003007 heart morphogenesis GO:0003143 embryonic heart tube morphogenesis GO:0006790 sulfur compound metabolic process GO:0007015 actin filament organization GO:0007368 determination of left/right symmetry GO:0007389 pattern specification process GO:0007507 heart development GO:0008154 actin polymerization or depolymerization GO:0009799 specification of symmetry GO:0009855 determination of bilateral symmetry GO:0010735 positive regulation of transcription via serum response element binding GO:0019417 sulfur oxidation GO:0030042 actin filament depolymerization GO:0032984 macromolecular complex disassembly GO:0035050 embryonic heart tube development GO:0035239 tube morphogenesis GO:0043241 protein complex disassembly GO:0043624 cellular protein complex disassembly GO:0048562 embryonic organ morphogenesis GO:0048568 embryonic organ development GO:0051261 protein depolymerization GO:0060562 epithelial tube morphogenesis GO:0061371 determination of heart left/right asymmetry |
Molecular Function |
GO:0003779 actin binding GO:0004497 monooxygenase activity GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016709 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen GO:0043914 NADPH:sulfur oxidoreductase activity GO:0048037 cofactor binding GO:0050660 flavin adenine dinucleotide binding GO:0050662 coenzyme binding GO:0071949 FAD binding |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MICAL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MICAL2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MICAL2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MICAL2 in various data sets.
|
Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MICAL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MICAL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MICAL2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MICAL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MICAL2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MICAL2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MICAL2 |
Name | microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Aliases | KIAA0750; MICAL-2PV1; MICAL2PV2; flavoprotein oxidoreductase MICAL2; microtubule associated monoxygenase, ca ...... |
Chromosomal Location | 11p15.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MICAL2 collected from DrugBank database. |
There is no record. |